PL3442583T3 - Zawierająca nikotynę kompozycja do leczenia krwawienia ze śluzówki lub błony śluzowej nosa - Google Patents

Zawierająca nikotynę kompozycja do leczenia krwawienia ze śluzówki lub błony śluzowej nosa

Info

Publication number
PL3442583T3
PL3442583T3 PL17782003.2T PL17782003T PL3442583T3 PL 3442583 T3 PL3442583 T3 PL 3442583T3 PL 17782003 T PL17782003 T PL 17782003T PL 3442583 T3 PL3442583 T3 PL 3442583T3
Authority
PL
Poland
Prior art keywords
nicotine
nasal
composition
treating bleeding
paranasal mucosa
Prior art date
Application number
PL17782003.2T
Other languages
English (en)
Inventor
Arturo Solis Herrera
Original Assignee
Arturo Solis Herrera
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901359A external-priority patent/AU2016901359A0/en
Application filed by Arturo Solis Herrera filed Critical Arturo Solis Herrera
Publication of PL3442583T3 publication Critical patent/PL3442583T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0601Apparatus for use inside the body
    • A61N5/0603Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0607Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0601Apparatus for use inside the body
    • A61N5/0603Apparatus for use inside the body for treatment of body cavities

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17782003.2T 2016-04-12 2017-04-12 Zawierająca nikotynę kompozycja do leczenia krwawienia ze śluzówki lub błony śluzowej nosa PL3442583T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016901359A AU2016901359A0 (en) 2016-04-12 Application of Nicotine Compounds to Nasal Membranes
PCT/IB2017/000764 WO2017178897A2 (en) 2016-04-12 2017-04-12 Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
PL3442583T3 true PL3442583T3 (pl) 2024-08-19

Family

ID=60042487

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17782003.2T PL3442583T3 (pl) 2016-04-12 2017-04-12 Zawierająca nikotynę kompozycja do leczenia krwawienia ze śluzówki lub błony śluzowej nosa

Country Status (15)

Country Link
US (1) US10639300B2 (pl)
EP (1) EP3442583B1 (pl)
JP (1) JP6770091B2 (pl)
KR (1) KR102199560B1 (pl)
CN (1) CN109069649A (pl)
AU (1) AU2017250514B2 (pl)
BR (1) BR122023020807A2 (pl)
CA (1) CA3014725C (pl)
ES (1) ES2984490T3 (pl)
HK (1) HK1258883A1 (pl)
MX (1) MX389596B (pl)
NZ (1) NZ744942A (pl)
PL (1) PL3442583T3 (pl)
RU (1) RU2718061C1 (pl)
WO (1) WO2017178897A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096932B2 (en) * 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
CN116251080A (zh) * 2023-02-16 2023-06-13 杭州师范大学 茄尼醇在制备预防、治疗或缓解慢性疼痛药物中的应用
CN120078753A (zh) * 2023-12-01 2025-06-03 北京生命科技研究院有限公司 茄尼醇在制备预防和/或治疗皮炎的药物中的用途
EP4623920A1 (en) * 2024-02-16 2025-10-01 The Catholic University Of Korea Industry-Academic Cooperation Foundation Pharmaceutical composition comprising inferior turbinate stem cells as active ingredient for preventing or treating secondary atrophic rhinitis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
MA23588A1 (fr) * 1994-06-23 1995-12-31 Procter & Gamble Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
CA2359813C (en) * 2000-10-24 2008-04-22 Richard L. Jones Nicotine mucosal spray
HU224941B1 (en) 2001-08-10 2006-04-28 Bgi Innovacios Kft Phototerapy apparatus
US20040254146A1 (en) 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US7273872B2 (en) 2002-12-06 2007-09-25 The Feinstein Institute For Medical Research Inhibition of inflammation using α 7 receptor-binding cholinergic agonists
EP1663168B1 (en) * 2003-09-08 2009-02-11 McNeil AB Nicotine formulations and use thereof
BRPI0513305A (pt) 2004-07-15 2008-05-06 Univ Laval agonistas do receptor nicotìnico para o tratamento de doenças inflamatórias
ES2683323T3 (es) 2006-05-08 2018-09-26 Arturo Solis Herrera El uso de nicotina en el tratamiento de la hemorragia postraumática en humanos
WO2008062453A2 (en) * 2006-09-25 2008-05-29 Nikki Nikhilesh Singh Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US9744375B2 (en) * 2010-08-05 2017-08-29 Allergia, Inc. Apparatus and methods for controlling and applying flash lamp radiation
CA2932464C (en) 2013-12-05 2023-01-03 Pax Labs, Inc. Nicotine liquid formulations for aerosol devices and methods thereof
CN104706556A (zh) 2015-03-31 2015-06-17 苏州维泰生物技术有限公司 抗过敏组合物及其在化妆品中的应用

Also Published As

Publication number Publication date
MX389596B (es) 2025-03-20
WO2017178897A2 (en) 2017-10-19
CA3014725C (en) 2020-09-22
EP3442583A2 (en) 2019-02-20
WO2017178897A3 (en) 2017-11-23
AU2017250514B2 (en) 2019-12-19
CA3014725A1 (en) 2017-10-19
AU2017250514A1 (en) 2018-08-23
EP3442583C0 (en) 2024-04-10
NZ744942A (en) 2020-08-28
KR20180108821A (ko) 2018-10-04
BR112018067718A2 (pt) 2019-01-08
MX2018012439A (es) 2019-02-21
JP2019511520A (ja) 2019-04-25
EP3442583B1 (en) 2024-04-10
ES2984490T3 (es) 2024-10-29
CN109069649A (zh) 2018-12-21
EP3442583A4 (en) 2019-12-25
HK1258883A1 (zh) 2019-11-22
BR122023020807A2 (pt) 2023-12-12
KR102199560B1 (ko) 2021-01-07
US10639300B2 (en) 2020-05-05
RU2718061C1 (ru) 2020-03-30
US20190111038A1 (en) 2019-04-18
JP6770091B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
IL261469A (en) Devices for vaporizing and inhaling nicotine
IL264156A (en) Compounds, preparations and methods for treating the disease
EP3400815A4 (en) GESCHMACKSINHALATOR
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
EP3263132C0 (en) Composition for treating il-6-related diseases
EP3377068C0 (en) COMBINATION THERAPY COMPRISING TETRACYCLIC QUINOLONE ANALOGUES FOR THE TREATMENT OF CANCER
EP3498297C0 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM
IL256684B (en) Medicinal compounds and preparations for the treatment of social disorders and substance use disorders
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
HUE049413T2 (hu) Nazális porkészítmény hipoglikémia kezelésére
PT3302573T (pt) Composição para o tratamento de lesões cerebrais
IL249640A0 (en) Preparations for the treatment of nosebleeds
PL3442583T3 (pl) Zawierająca nikotynę kompozycja do leczenia krwawienia ze śluzówki lub błony śluzowej nosa
GB201612043D0 (en) Composition for treatment of disorders
PT3302523T (pt) Composição para o tratamento de lesões tecidulares
EP3375450A4 (en) COMPOSITION FOR THE TREATMENT OF APOPLEXIA OVER NASAL ADMINISTRATION
PL3261683T3 (pl) Kompozycja do stosowania miejscowego do leczenia uszkodzeń błony śluzowej
SG11202002088TA (en) Methods and compositions for treating chronic lung diseases
PL3285791T3 (pl) Kompozycja do leczenia gardła/jamy gardłowej
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
SMT202400230T1 (it) Composizioni comprendenti acido cromoglicico per il trattamento della dermatite
KR101912544B9 (ko) 어큐빈을 포함하는 신경정신 질환의 예방 또는 치료용 조성물
IL253878A0 (en) An effective substance for the treatment of respiratory inflammation
HK40004860B (en) Composition comprising nicotine for treating bleeding of the nasal or paranasal mucosa